Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
about
Poststroke Cell Therapy of the Aged BrainThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseMethotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.CCR7 expressing mesenchymal stem cells potently inhibit graft-versus-host disease by spoiling the fourth supplemental Billingham's tenetApplication of Umbilical Cord Blood Derived Stem Cells in Diseases of the Nervous SystemEx vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodIncreased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.Umbilical cord blood graft engineering: challenges and opportunities.Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.Immunotherapy after hematopoietic stem cell transplantation using umbilical cord blood-derived products.Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.Third-party regulatory T cells prevent murine acute graft-versus-host disease.Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
P2860
Q26782735-7FAD1055-4702-4B96-AF73-0087E97A23FDQ28076264-F7351993-E9CA-4346-B1EF-B334BFA4D699Q34487408-8F93AB68-F001-4BEF-81F3-96D9A07DFF8CQ34790016-45063971-E8AB-4398-B96E-0A3277A279CDQ34975310-B1D194AC-95B7-45B2-9D2C-A64E45D9FC16Q35126283-E0F8AFF4-15A6-4F17-863B-8D1F4DD20FEDQ35582326-04AE0E2A-5552-4983-9F8E-DF94AFAD44A1Q36036340-F213FD9D-2F10-4E8A-8EB3-0CB19B75C94BQ38514503-E13B64BA-5D7C-4788-AAF4-0CAC0ADB4EFBQ38839367-15FB3C87-E4D9-402C-9053-BB3EE6182336Q38857841-3DC0C67E-DE74-4384-B9CE-6BFEE756817CQ41658163-33F6B669-BD55-478E-B6E5-B54417C73684Q42719240-CD229339-C84C-4EA0-B679-F73623FC80F6Q46059376-66AF27DB-31BA-43E9-B1C8-4F62B6BB6FB8Q48626100-AEFCDF9F-D06E-45D3-A8C4-3A9CC1B963B9Q52682313-81725033-4C51-4986-A3E2-E8A0399D5CDDQ55322285-22D30A14-8464-415C-B20F-ED6199C6E5F7
P2860
Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@en
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@nl
type
label
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@en
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@nl
prefLabel
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@en
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@nl
P2093
P2860
P1433
P1476
Third-party umbilical cord blo ...... nic graft-versus-host disease.
@en
P2093
Amer Najjar
Barbara Savoldo
Catherine M Bollard
Elizabeth J Shpall
Gabriel Rodriguez
Ian McNiece
Jeffery J Molldrem
P2860
P304
P356
10.1016/J.JCYT.2013.07.009
P577
2013-10-26T00:00:00Z